Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Localized immune modulation with rapamycin-eluting micelles to preserve pancreatic islet graft function
EF 2021-22
Résumé
Introduction: Islet transplantation is an effective way that type 1 diabetic patients can be freed from insulin injections, however the lifelong immunosuppression required to subvert the immune response remains a major barrier. Chronic systemic (affecting whole body) immunosuppression often results in multiple toxicities that can reduce the quality of life of transplant recipients. This project explores the use of a localized drug delivery system to preserve transplanted islet function and potentially circumvent the need for systemic immunosuppression.Poly(lactic-co-glycolic acid) is an FDA-approved biomaterial that can form particles that encapsulate and releases drugs. Rapamycin (rapa) is a potent immunosuppressant used in clinical islet transplantation, and its chemical properties makes it an ideal candidate for PLGA particle encapsulation. We hypothesize that this localized rapa-releasing system will subvert the immune response pathways, promoting long-term durable islet function in a transplanted diabetic mouse model under the skin.Methods: Rapa-releasing particles were made and characterized: encapsulation efficiency, structure, and rate of drug release. To examine immune unrelated effects of rapa particles on transplanted islet function, we co-transplanted syngeneic islet (genetically identical recipient and donor). Later, we will use an allogenic diabetic mouse model (non-identical donor and recipient) to determine how well rapa particles can prolonging allograft function. Graft function is monitored through blood glucose levels: non-fasted and fasted following glucose injection.Conclusion: If our hypothesis holds true, rapa particles has the potential to replace chronic systemic immunosuppression and its associated toxicities in islet transplantation.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466784
Name
Wong Jordan
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Localized immune modulation with rapamycin-eluting micelles to preserve pancreatic islet graft function
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomaterials; Immunology; In Vivo; Islet Biology; Islet Transplantation; Local Immunomodulation; Microparticles; Preclinical; Surgery; Type 1 Diabetes
Abstract
Introduction: Islet transplantation is an effective way that type 1 diabetic patients can be freed from insulin injections, however the lifelong immunosuppression required to subvert the immune response remains a major barrier. Chronic systemic (affecting whole body) immunosuppression often results in multiple toxicities that can reduce the quality of life of transplant recipients. This project explores the use of a localized drug delivery system to preserve transplanted islet function and potentially circumvent the need for systemic immunosuppression.Poly(lactic-co-glycolic acid) is an FDA-approved biomaterial that can form particles that encapsulate and releases drugs. Rapamycin (rapa) is a potent immunosuppressant used in clinical islet transplantation, and its chemical properties makes it an ideal candidate for PLGA particle encapsulation. We hypothesize that this localized rapa-releasing system will subvert the immune response pathways, promoting long-term durable islet function in a transplanted diabetic mouse model under the skin.Methods: Rapa-releasing particles were made and characterized: encapsulation efficiency, structure, and rate of drug release. To examine immune unrelated effects of rapa particles on transplanted islet function, we co-transplanted syngeneic islet (genetically identical recipient and donor). Later, we will use an allogenic diabetic mouse model (non-identical donor and recipient) to determine how well rapa particles can prolonging allograft function. Graft function is monitored through blood glucose levels: non-fasted and fasted following glucose injection.Conclusion: If our hypothesis holds true, rapa particles has the potential to replace chronic systemic immunosuppression and its associated toxicities in islet transplantation.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wong, Jordan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~